Ohio delays executions until 2017 over lack of lethal drugs

Execution dates for 11 inmates scheduled to die next year and one scheduled for early 2017 were all pushed into ensuing years through warrants of reprieve issued by Gov. John Kasich.

AP Photo/Scott Osborne, File
In this April 24, 2007, file photo, a hearse carries the body of James Filiaggi from Southern Ohio Correctional Facility in Lucasville, Ohio, following his execution for killing his ex-wife in 1994. On Monday, Oct. 19, 2015, officials from the Ohio Department of Rehabilitation and Correction announced a two-year delay in capital punishment as the state struggles to obtain lethal injection drugs, after Gov. John Kasich issued warrants of reprieve postponing executions of a dozen inmates until at least 2017.

Ohio is putting off executions until at least 2017 as the state struggles to obtain supplies of lethal injection drugs, delaying capital punishment for a full two years, the prisons department announced Monday.

Execution dates for 11 inmates scheduled to die next year and one scheduled for early 2017 were all pushed into ensuing years through warrants of reprieve issued by Gov. John Kasich.

The result is 25 inmates with execution dates beginning in January 2017 that are now scheduled through August 2019. Ohio last put someone to death in January 2014.

Ohio has run out of supplies of its previous drugs and has unsuccessfully sought new amounts, including so-far failed attempts to import chemicals from overseas.

The new dates are needed to give the prisons agency extra time, the Department of Rehabilitation and Correction said in a statement.

The agency "continues to seek all legal means to obtain the drugs necessary to carry out court ordered executions, but over the past few years it has become exceedingly difficult to secure those drugs because of severe supply and distribution restrictions," the statement said.

Last week, the attorney general's office in Oklahoma announced no executions will be scheduled until at least next year as the office investigates why the state used the wrong drug during a lethal injection in January and nearly did so again last month.

Earlier this month, an Arkansas judge halted the upcoming executions of eight death row inmates who are challenging a new law that allows the state to withhold any information that could publicly identify the manufacturers or sellers of its execution drugs.

On Oct. 1, Virginia executed serial killer Alfredo Prieto, but only after obtaining pentobarbital from the Texas prison system. Texas has continued to purchase supplies of compounded pentobarbital without saying how much it has obtained or where it came from.

At Ohio's last execution in 2014, condemned killer Dennis McGuire died fitfully over 26-minutes, the longest in Ohio history, as a new two-drug combo was used.

The next execution, of Ronald Phillips, was scheduled for Jan. 21, but was rescheduled for Jan. 12, 2017.

The handwriting has been on the wall for months that Ohio would have to make such a move, said Franklin County Prosecutor Ron O'Brien, expressing his frustration at a new set of delays.

These delays come in cases where inmates have long exhausted their appeals and there's no question of their guilt, he said.

"It seems that in those states that authorize assisted suicide, there has been no impediment to securing drugs, and as time marches onward, victims wonder why they must continue to wait for justice," O'Brien said in an email.

Ohio abandoned the two-drug method after McGuire's execution and announced it would use either of two older drugs that it had previously obtained for capital punishment, but did not currently have supplies of.

One of those drugs, sodium thiopental, is no longer manufactured by FDA-approved companies and the other, pentobarbital, has been put off limits for executions by drug makers.

Ohio obtained a federal import license to seek supplies overseas, but has been told by the FDA that such a move is illegal. Ohio raised the issue again with the FDA earlier this month, asserting the state believes it can obtain a lethal-injection drug from overseas without violating any laws. The FDA has yet to respond.

You've read  of  free articles. Subscribe to continue.

Dear Reader,

About a year ago, I happened upon this statement about the Monitor in the Harvard Business Review – under the charming heading of “do things that don’t interest you”:

“Many things that end up” being meaningful, writes social scientist Joseph Grenny, “have come from conference workshops, articles, or online videos that began as a chore and ended with an insight. My work in Kenya, for example, was heavily influenced by a Christian Science Monitor article I had forced myself to read 10 years earlier. Sometimes, we call things ‘boring’ simply because they lie outside the box we are currently in.”

If you were to come up with a punchline to a joke about the Monitor, that would probably be it. We’re seen as being global, fair, insightful, and perhaps a bit too earnest. We’re the bran muffin of journalism.

But you know what? We change lives. And I’m going to argue that we change lives precisely because we force open that too-small box that most human beings think they live in.

The Monitor is a peculiar little publication that’s hard for the world to figure out. We’re run by a church, but we’re not only for church members and we’re not about converting people. We’re known as being fair even as the world becomes as polarized as at any time since the newspaper’s founding in 1908.

We have a mission beyond circulation, we want to bridge divides. We’re about kicking down the door of thought everywhere and saying, “You are bigger and more capable than you realize. And we can prove it.”

If you’re looking for bran muffin journalism, you can subscribe to the Monitor for $15. You’ll get the Monitor Weekly magazine, the Monitor Daily email, and unlimited access to CSMonitor.com.